Commercial Analytics · Testing Gaps
A patient can only receive a targeted therapy after the right biomarker test. Hyperdrive inpatient pathology data shows where that testing falls short, by provider, hospital and site of care, so biopharma and diagnostics teams can see the gap and work to close it.
2M
Pathology reports a year
1.5M
Biomarker results a year
3.8M+
New patient cases a year, across indications
Claims and prescription data show patients who were tested and treated. They cannot show the patient whose cancer was diagnosed but never tested for the biomarker that would have made them eligible.
Pathology data starts earlier. The diagnosis is recorded in the pathology report, so a confirmed case without a matching biomarker result shows up as a gap, at the provider and hospital where it happened.
01
Confirmed cases with no matching biomarker result, by indication and biomarker.
02
Gaps resolved to the ordering and treating physician, the hospital and the care setting.
03
Which cases received single-gene testing, panels or comprehensive genomic profiling, and where testing stopped short.
04
Track whether education and access programs move testing at the accounts they target.
Medical affairs, market access and field teams decide where education and access work will matter most.
For biopharma
See where a test is underused and which providers and hospitals to reach.
For diagnostics
Get notified the same day a provider’s testing changes for the biomarkers you track.
See HCP Alerts
A patient with a confirmed diagnosis who did not receive the biomarker testing that would determine eligibility for a targeted therapy. Hyperdrive shows where those gaps occur, by provider, hospital and site of care.
From pathology and genomics reference labs in the Hyperdrive Lab Data Network, including inpatient pathology data, linked to curated public provider and hospital data.
No. Data is de-identified under the HIPAA Safe Harbor method or by Expert Determination and summarized to the individual healthcare provider.
As prospective weekly data with lookbacks, or as custom analyses for a specific indication, biomarker or geography.
Tell us the indication, the biomarker and the geography. We will show you where testing falls short and the providers behind it, on data you can check.